The MarketReader Minute
(IBB) has seen a 0.5% increase today, coinciding with the ongoing U.S. presidential election, where Vice President Kamala Harris and former President Donald Trump are in a competitive race that may affect financial markets, including biotechnology.
The MarketReader Minute
(IBB) has seen a decrease of 0.1% since Friday. In the previous week, from October 28 to November 1, the ETF recorded a gain of 0.90%, reaching a price of 142.78. Key contributors to this performance included GILD, ILMN, APLS, HALO, and MTD, each registering positive returns.
The MarketReader Minute
(IBB) has experienced a decline of 1.2% since Wednesday. The U.S. private sector added 233,000 jobs in October, surpassing expectations and highlighting robust labor market conditions, while GDP growth slowed unexpectedly to an annualized rate of 2.8% for Q3.
The MarketReader Minute
The iShares Biotechnology ETF (IBB) has seen a price increase of 0.4% since Tuesday. Notable contributors to this performance include Neurocrine Biosciences Inc (NBIX), (EXEL) .
The MarketReader Minute
(IBB) has increased by 1.1% since Friday, buoyed by significant movements among its holdings. Moderna Inc. (MRNA) has experienced a notable rise following the initiation of its Phase 3 clinical trial for lung cancer patients.
The MarketReader Minute
(IBB) has seen a decline of 0.2% since Wednesday. Key contributors to this performance included IQV, which dropped significantly. Moderna Inc. experienced a modest decline and received a price target reduction from UBS, while Piper Sandler maintained an Overweight rating.
The MarketReader Minute
(IBB) has declined by 1.5% during market hours on Wednesday. Recent social media discussions have noted a prediction from betting markets of a Republican sweep in the upcoming November elections, which could benefit IBB.
The MarketReader Minute
The iShares Biotechnology ETF (IBB) has declined by 1.1% since Friday, coinciding with a broader market trend reflected in the Russell 2000 Index, which has dropped by nearly 1%.
The MarketReader Minute
The FDA approved Novocure's Optune Lua for treating metastatic non-small cell lung cancer, marking an advancement in biotechnology treatment options. (WVE) reported an achievement in RNA medicine, successfully conducting the first therapeutic RNA editing in humans for alpha-1 antitrypsin deficiency.
The MarketReader Minute
The iShares Biotechnology ETF (IBB) has experienced a price increase of 1.3% since Thursday. Key contributors to this performance include MRNA, which rose significantly, followed by REGN and AMGN with moderate gains.
The MarketReader Minute
Among the ETF's holdings, notable contributors to performance include BNTX, SRPT, HALO, MDGL, and MRNA, all of which experienced declines. Additionally, the iShares iBoxx $ High Yield Corporate Bond ETF (HYG) has decreased, reflecting broader market sentiment that may also influence the IBB.
The MarketReader Minute
The iShares Biotechnology ETF (IBB) has experienced a price decline since Friday. Recent conversations on social media indicate that long buys outpaced short sales, with a ratio of 2.3 to 1, as reported by Goldman.
